Takeda acquires target for cardiovascular disease research

Published: 3-Mar-2006

Takeda Pharmaceutical Co has selected LG474, discovered by Lexicon Genetics in its Genome5000 programme, as a target for drug discovery in the cardiovascular field. It has paid Lexicon Genetics a US$5m research milestone for the target.


Takeda Pharmaceutical Co has selected LG474, discovered by Lexicon Genetics in its Genome5000 programme, as a target for drug discovery in the cardiovascular field. It has paid Lexicon Genetics a US$5m research milestone for the target.

In July 2004, Takeda and Lexicon entered into an alliance to develop new drugs from hypertension targets from Lexicon's Genome5000 programme. In that collaboration, Takeda has exclusive access to all drug targets for a three-year term and will evaluate and verify the targets to create new drugs. Takeda is responsible for the screening, medical chemistry, pre-clinical and clinical development and commercialisation of drugs directed against Lexicon's targets, and bears all related costs.

Takeda paid an upfront payment of US$12m to Lexicon upon conclusion of the agreement in July 2004, and will also pay research, development and launch milestones as well as royalties once the product is launched.

'We are pleased to start a research study of LG474 as the first target that we have selected under this collaboration with Lexicon Genetics,' said Shigenori Ohkawa, general manager of Takeda's pharmaceutical research division. 'We expect this research to lead to the discovery of new drugs for cardiovascular diseases.'

See more

You may also like

Regulatory

Takeda receives FDA clearance for HyHub devices to simplify HYQVIA administration

Read more
Needle-free infusion tools aim to improve in-home treatment for primary immunodeficiency and CIDP

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Abselion launches AAVX and AAV9 Total Capsid Quantification Kits Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
  3. diaago and Peak Analysis & Automation partner to bring practical automation solutions to research laboratories Using diaago's customer-first approach with PAA’s decades of expertise in laboratory robotics, the collaboration promises to deliver solutions to streamline workflows, boost throughput and reduce bottlenecks
  4. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  5. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Regulatory

Takeda receives FDA clearance for HyHub devices to simplify HYQVIA administration

Needle-free infusion tools aim to improve in-home treatment for primary immunodeficiency and CIDP
Research & Development

Nanoform and Takeda team up to advance plasma-derived therapy development

The collaboration will aim to develop plasma-derived therapeutics and accelerate the movement of potential medicines into the clinic
Manufacturing

Takeda's NDA for metastatic colorectal cancer treatment

The FDA has granted priority review of the New Drug Application for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors
Finance

Takeda Pharmaceutical to acquire GammaDelta Therapeutics

Abingworth was the founding investor in GammaDelta and provided initial seed funding as part of the company’s creation in 2016
Finance

Takeda to evaluate Aptamer Group reagents for drug development

Based on oligonucleotide molecules, Optimers (which the company describes as optimised aptamer reagents) can bind specifically to a target molecule to act as an antibody alternative
Finance

Adaptate Biotherapeutics raises $18 m in Series A2 funding

The financing will also support the company’s expansion, including further recruitment and increased laboratory and office space
Finance

Novadiscovery enters clinical simulation collaboration with Takeda

This agreement builds on an existing relationship between the companies that began in 2017
Subscribe now